Premium
Review: new aminosalicylic acid derivatives for the treatment of inflammatory bowel disease
Author(s) -
ARVIND A. S.,
FARTHING M. J. G.
Publication year - 1988
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1988.tb00699.x
Subject(s) - aminosalicylic acid , medicine , ulcerative colitis , inflammatory bowel disease , colitis , sulfasalazine , adverse effect , gastroenterology , mesalazine , crohn disease , disease , intensive care medicine
SUMMARY Up to 20–30% of patients treated with sulphasalazine experience a variety of adverse effects, principally due to the carrier moiety sulphapyridine. In the last decade there has been a major drive to develop a new generation of 5‐aminosalicylic acid (5‐ASA) and 5‐ASA‐related drugs which not only have a high efficacy but are also devoid of the unwanted side‐effects of sulphapyridine. Various forms of 5‐ASA have been evaluated in ulcerative colitis and appear to be effective orally in preventing relapse and topically in the treatment of active distal colitis. More recently, topical 4‐ASA has been found to be useful for the treatment of distal colitis with the advantage of better stability and lower cost compared with 5‐ASA. In the foreseeable future it seems likely that these new aminosalicylic acid derivatives will become the drugs of choice in the treatment of inflammatory bowel disease and largely replace sulphasalazine.